- Home
- CBOE vs BIIB Comparison
CBOE vs BIIB Comparison
Compare CBOE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBOE | BIIB |
|---|---|---|
| Founded | 1973 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6B | 24.2B |
| IPO Year | 2010 | 1991 |
Fundamental Metrics
Financial Performance| Metric | CBOE | BIIB |
|---|---|---|
| Price | $246.08 | $175.30 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 22 |
| Target Price | ★ $244.64 | $177.40 |
| AVG Volume (30 Days) | 649.7K | ★ 2.0M |
| Earning Date | 10-31-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | ★ 26.68 | N/A |
| EPS | 9.30 | ★ 10.97 |
| Revenue | $4,617,800,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | N/A | $3.61 |
| Revenue Next Year | $5.52 | N/A |
| P/E Ratio | $27.21 | ★ $15.86 |
| Revenue Growth | ★ 16.74 | 4.77 |
| 52 Week Low | $187.30 | $110.04 |
| 52 Week High | $262.98 | $185.17 |
Technical Indicators
Market Signals| Indicator | CBOE | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 56.69 |
| Support Level | $247.68 | $169.24 |
| Resistance Level | $254.52 | $180.79 |
| Average True Range (ATR) | 4.37 | 5.04 |
| MACD | -1.28 | -1.57 |
| Stochastic Oscillator | 8.86 | 42.85 |
Price Performance
Historical ComparisonAbout CBOE Cboe Global Markets Inc.
Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).